Hit by several delays for its gene therapy programs, Bluebird bio Inc (NASDAQ:BLUE) ended 2021 with a cash and equivalents balance of approximately $442 million. The full-year 2022 cash burn is expected to be less than $400 million.
The company's expectation of generating operating losses and negative operating cash flows and the need for additional funding to support its planned operations raise substantial doubt regarding its ability to continue as a going concern.
